SCHEMBL4248501

SCHEMBL4248501

O=S(=O)(OS(=O)(=O)C(F)(F)F)C(F)(F)F.[O-][S+](c1ccccc1)N1CCCCC1.[O-][S+](c1ccccc1)N1CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.35
HTT P42858 3/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 2/20 0.33
TSHR P16473 4/20 0.33
ALDH1A1 P00352 4/20 0.33
GAA P10253 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.31
DRD2 P14416 1/20 0.31
DRD1 P21728 1/20 0.31
DRD4 P21917 1/20 0.31
DRD5 P21918 1/20 0.31
DRD3 P35462 1/20 0.31
USP2 O75604 1/20 0.31
MCOLN3 Q8TDD5 2/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9978566 1.00 LMNA (0.35) LMNAHTTMAPK1SMN1; SMN2HPGD
SCHEMBL1259047 0.81 KCNH2 (0.38) LMNAHTTHPGDALDH1A1CYP3A4
SCHEMBL20919908 0.81 KCNH2 (0.38) LMNAHTTHPGDALDH1A1CYP3A4
SCHEMBL20195364 0.79 KCNH2 (0.35) HPGDTSHRALDH1A1GAACYP3A4
SCHEMBL8698034 0.72 SIGMAR1 (0.31) MEN1KMT2A
SCHEMBL23368545 0.67 TDP1 (0.38) LMNAHTTMAPK1SMN1; SMN2TSHR
SCHEMBL3779703 0.66 RECQL (0.31)
SCHEMBL10884878 0.65 ALDH1A1 (0.45) HTTSMN1; SMN2HPGDTSHRALDH1A1
SCHEMBL6677443 0.64 LMNA (0.45) LMNAHTTSMN1; SMN2TSHRALDH1A1
SCHEMBL22643223 0.64 HPGD (0.36) LMNASMN1; SMN2HPGDALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2723754-B1 MULTIVALENT [BETA]-1-2-LINKED MANNOSE OLIGOSACCHARIDES AS IMMUNOSTIMULATORY COMPOUNDS AND USES THEREOF TURUN YLIOPISTO (FI) 2017-03-22 EP disclosed
US-9221861-B2 Multivalent [beta]-1-2-linked mannose oligosaccharides as immunostimulatory compounds and uses thereof ABO AKADEMI UNIVERSITY (FI) 2015-12-29 US disclosed
EP-2723754-A1 MULTIVALENT [BETA]- 1 - 2 - LINKED MANNOSE OLIGOSACCHARIDES AS IMMUNOSTIMULATORY COMPOUNDS AND USES THEREOF Turun Yliopisto (FI) 2014-04-30 EP disclosed
US-20140105932-A1 MULTIVALENT [BETA] - 1 - 2 - LINKED MANNOSE OLIGOSACCHARIDES AS IMMUNOSTIMULATORY COMPOUNDS AND USES THEREOF ÅBO AKADEMI UNIVERSITY (FI) 2014-04-17 US disclosed
WO-2012175813-A1 MULTIVALENT [BETA] - 1 - 2 - LINKED MANNOSE OLIGOSACCHARIDES AS IMMUNOSTIMULATORY COMPOUNDS AND USES THEREOF TURUN YLIOPISTO (FI) 2012-12-27 WO disclosed
US-20090247732-A1 Synthesis of glycopeptides with superior pharmacokinetic properties OPTIMER PHARMACEUTICALS, INC. (US) 2009-10-01 US disclosed
WO-2005044197-A2 SYNTHESIS OF GLYCOPEPTIDES WITH SUPERIOR PHARMACOKINETIC PROPERTIES OPTIMER PHARMACEUTICALS, INC. (US) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140105932-A1 MULTIVALENT [BETA] - 1 - 2 - LINKED MANNOSE OLIGOSACCHARIDES AS IMMUNOSTIMULATORY COMPOUNDS AND USES THEREOF CD4, MAN2A1, MANBA LMNA 4829/4885HTT 3795/4885MAPK1 1238/4885
US-20090247732-A1 Synthesis of glycopeptides with superior pharmacokinetic properties VIP, MGAT3, UGGT1 LMNA 3832/4885HTT 2626/4885MAPK1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.